medcitynews.com
Open in
urlscan Pro
2606:4700:20::681a:350
Public Scan
Submitted URL: http://go.pardot.com/e/710433/roup-of-rare-genetic-diseases-/dcqww/486265625?h=bViKKCZjj6aY02UWy768_h3HjosWikJcJZ4h3b...
Effective URL: https://medcitynews.com/2022/04/novartis-cancer-drug-is-now-first-approved-therapy-for-group-of-rare-genetic-diseases/
Submission: On April 07 via api from US — Scanned from DE
Effective URL: https://medcitynews.com/2022/04/novartis-cancer-drug-is-now-first-approved-therapy-for-group-of-rare-genetic-diseases/
Submission: On April 07 via api from US — Scanned from DE
Form analysis 6 forms found in the DOM
GET https://medcitynews.com/
<form method="get" class="search" action="https://medcitynews.com/" role="search">
<input type="text" class="field" name="s" value="" id="s" placeholder="Search …">
<button type="submit"><i class="fa fa-search"></i></button>
</form>GET https://medcitynews.com/
<form method="get" class="search" action="https://medcitynews.com/" role="search">
<input type="text" class="field" name="s" value="" id="s" placeholder="Search …">
<button type="submit"><i class="fa fa-search"></i></button>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data"
id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" method="POST"
class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_c2e10894-82ef-41b1-9c1e-3f8f76cd435d"
data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" data-reactid=".hbspt-forms-0">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-0.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" class=""
placeholder="Enter your " for="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" data-reactid=".hbspt-forms-0.1:$0.0"><span data-reactid=".hbspt-forms-0.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-0.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" class="hs-input" type="email" name="email" required=""
placeholder="Your email address*" value="" autocomplete="email" data-reactid=".hbspt-forms-0.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-0.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-0.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-0.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-0.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-0.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-0.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":2137,"rumServiceResponseTime":2741.2999992370605,"rumFormRenderTime":2.700000762939453,"rumTotalRenderTime":4825,"rumTotalRequestTime":592.3999977111816,"embedAtTimestamp":"1649341567892","formDefinitionUpdatedAt":"1464813666301","pageUrl":"https://medcitynews.com/2022/04/novartis-cancer-drug-is-now-first-approved-therapy-for-group-of-rare-genetic-diseases/","pageTitle":"Novartis cancer drug is now first approved therapy for group of rare, genetic diseases - MedCity News","source":"FormsNext-static-5.467","sourceName":"FormsNext","sourceVersion":"5.467","sourceVersionMajor":"5","sourceVersionMinor":"467","timestamp":1649341567894,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/100.0.4896.75 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"a93d8b4e-029d-4de9-9599-c09510e52983","target":"#newsletter-form-mobile-interstitial","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial","renderedFieldsIds":["email"],"formTarget":"#newsletter-form-mobile-interstitial","correlationId":"03e299fa-18af-4150-a606-4e94645792c6","hutk":"ef9f9bed8eeda466125adee58f02016b","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-0.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-mobile-interstitial" style="display:none;" data-reactid=".hbspt-forms-0.8"></iframe>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data" id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983"
method="POST" class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_18f06aef-f37a-4c79-9111-2e83806b3d98"
data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983" data-reactid=".hbspt-forms-3">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-3.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983" class="" placeholder="Enter your " for="email-a93d8b4e-029d-4de9-9599-c09510e52983"
data-reactid=".hbspt-forms-3.1:$0.0"><span data-reactid=".hbspt-forms-3.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-3.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-3.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983" class="hs-input" type="email" name="email" required="" placeholder="Your email address*" value="" autocomplete="email"
data-reactid=".hbspt-forms-3.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-3.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-3.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-3.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-3.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-3.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-3.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":2395,"rumServiceResponseTime":5136,"rumFormRenderTime":2.299999237060547,"rumTotalRenderTime":5155,"rumTotalRequestTime":232.79999923706055,"embedAtTimestamp":"1649341570566","formDefinitionUpdatedAt":"1464813666301","pageUrl":"https://medcitynews.com/2022/04/novartis-cancer-drug-is-now-first-approved-therapy-for-group-of-rare-genetic-diseases/","pageTitle":"Novartis cancer drug is now first approved therapy for group of rare, genetic diseases - MedCity News","source":"FormsNext-static-5.467","sourceName":"FormsNext","sourceVersion":"5.467","sourceVersionMajor":"5","sourceVersionMinor":"467","timestamp":1649341570568,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/100.0.4896.75 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"a93d8b4e-029d-4de9-9599-c09510e52983","target":"#signup-main-hubspot","redirectUrl":"http://medcitynews.com/youre-subscribed/"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","renderedFieldsIds":["email"],"formTarget":"#signup-main-hubspot","correlationId":"39425aeb-2355-4960-8fd5-63b40c14f25b","hutk":"ef9f9bed8eeda466125adee58f02016b","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-3.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983" style="display:none;" data-reactid=".hbspt-forms-3.8"></iframe>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/a93d8b4e-029d-4de9-9599-c09510e52983" enctype="multipart/form-data"
id="hsForm_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" method="POST"
class="hs-form stacked hs-form-private hsForm_a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983 hs-form-a93d8b4e-029d-4de9-9599-c09510e52983_33d448eb-7b73-4ce4-8d51-2c2a87a613bd"
data-form-id="a93d8b4e-029d-4de9-9599-c09510e52983" data-portal-id="2097126" target="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" data-reactid=".hbspt-forms-1">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-1.1:$0"><label id="label-email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" class="" placeholder="Enter your "
for="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" data-reactid=".hbspt-forms-1.1:$0.0"><span data-reactid=".hbspt-forms-1.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-1.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-1.1:$0.$email"><input id="email-a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" class="hs-input" type="email" name="email" required=""
placeholder="Your email address*" value="" autocomplete="email" data-reactid=".hbspt-forms-1.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-1.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-1.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-1.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-1.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-1.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-1.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":2395,"rumServiceResponseTime":2746.2000007629395,"rumFormRenderTime":2.3000030517578125,"rumTotalRenderTime":4855.900001525879,"rumTotalRequestTime":337.70000076293945,"embedAtTimestamp":"1649341568134","formDefinitionUpdatedAt":"1464813666301","pageUrl":"https://medcitynews.com/2022/04/novartis-cancer-drug-is-now-first-approved-therapy-for-group-of-rare-genetic-diseases/","pageTitle":"Novartis cancer drug is now first approved therapy for group of rare, genetic diseases - MedCity News","source":"FormsNext-static-5.467","sourceName":"FormsNext","sourceVersion":"5.467","sourceVersionMajor":"5","sourceVersionMinor":"467","timestamp":1649341568138,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/100.0.4896.75 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"a93d8b4e-029d-4de9-9599-c09510e52983","target":"#newsletter-form-sidebar","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-sidebar"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","formInstanceId":"a93d8b4e-029d-4de9-9599-c09510e52983-sidebar","renderedFieldsIds":["email"],"formTarget":"#newsletter-form-sidebar","correlationId":"c358ce1f-a7bf-4194-b411-529ef7f5b400","hutk":"ef9f9bed8eeda466125adee58f02016b","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-1.7"><iframe name="target_iframe_a93d8b4e-029d-4de9-9599-c09510e52983_a93d8b4e-029d-4de9-9599-c09510e52983-sidebar" style="display:none;" data-reactid=".hbspt-forms-1.8"></iframe>
</form>POST https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/30083c7c-72db-412b-8a6e-e72e5b9308ce
<form novalidate="" accept-charset="UTF-8" action="https://forms.hsforms.com/submissions/v3/public/submit/formsnext/multipart/2097126/30083c7c-72db-412b-8a6e-e72e5b9308ce" enctype="multipart/form-data" id="hsForm_30083c7c-72db-412b-8a6e-e72e5b9308ce"
method="POST" class="hs-form stacked hs-form-private hsForm_30083c7c-72db-412b-8a6e-e72e5b9308ce hs-form-30083c7c-72db-412b-8a6e-e72e5b9308ce hs-form-30083c7c-72db-412b-8a6e-e72e5b9308ce_b482bba6-62df-4809-9201-432e8fe261f7"
data-form-id="30083c7c-72db-412b-8a6e-e72e5b9308ce" data-portal-id="2097126" target="target_iframe_30083c7c-72db-412b-8a6e-e72e5b9308ce" data-reactid=".hbspt-forms-2">
<div class="hs_email hs-email hs-fieldtype-text field hs-form-field" data-reactid=".hbspt-forms-2.1:$0"><label id="label-email-30083c7c-72db-412b-8a6e-e72e5b9308ce" class="" placeholder="Enter your " for="email-30083c7c-72db-412b-8a6e-e72e5b9308ce"
data-reactid=".hbspt-forms-2.1:$0.0"><span data-reactid=".hbspt-forms-2.1:$0.0.0"></span></label>
<legend class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-2.1:$0.1"></legend>
<div class="input" data-reactid=".hbspt-forms-2.1:$0.$email"><input id="email-30083c7c-72db-412b-8a6e-e72e5b9308ce" class="hs-input" type="email" name="email" required="" placeholder="Your email address*" value="" autocomplete="email"
data-reactid=".hbspt-forms-2.1:$0.$email.0" inputmode="email"></div>
</div><noscript data-reactid=".hbspt-forms-2.2"></noscript>
<div class="hs_submit hs-submit" data-reactid=".hbspt-forms-2.5">
<div class="hs-field-desc" style="display:none;" data-reactid=".hbspt-forms-2.5.0"></div>
<div class="actions" data-reactid=".hbspt-forms-2.5.1"><input type="submit" value="Subscribe" class="hs-button primary large" data-reactid=".hbspt-forms-2.5.1.0"></div>
</div><noscript data-reactid=".hbspt-forms-2.6"></noscript><input name="hs_context" type="hidden"
value="{"rumScriptExecuteTime":2395,"rumServiceResponseTime":5136,"rumFormRenderTime":1.7000007629394531,"rumTotalRenderTime":5137.900001525879,"rumTotalRequestTime":234.4000015258789,"embedAtTimestamp":"1649341570560","formDefinitionUpdatedAt":"1464813456785","pageUrl":"https://medcitynews.com/2022/04/novartis-cancer-drug-is-now-first-approved-therapy-for-group-of-rare-genetic-diseases/","pageTitle":"Novartis cancer drug is now first approved therapy for group of rare, genetic diseases - MedCity News","source":"FormsNext-static-5.467","sourceName":"FormsNext","sourceVersion":"5.467","sourceVersionMajor":"5","sourceVersionMinor":"467","timestamp":1649341570563,"userAgent":"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/100.0.4896.75 Safari/537.36","originalEmbedContext":{"portalId":"2097126","formId":"30083c7c-72db-412b-8a6e-e72e5b9308ce","target":"#interstitial_hubspot","redirectUrl":"http://medcitynews.com/youre-subscribed/"},"redirectUrl":"http://medcitynews.com/youre-subscribed/","renderedFieldsIds":["email"],"formTarget":"#interstitial_hubspot","correlationId":"acfad69d-f1a8-4fac-8181-b00ffd8e442b","hutk":"ef9f9bed8eeda466125adee58f02016b","captchaStatus":"NOT_APPLICABLE"}"
data-reactid=".hbspt-forms-2.7"><iframe name="target_iframe_30083c7c-72db-412b-8a6e-e72e5b9308ce" style="display:none;" data-reactid=".hbspt-forms-2.8"></iframe>
</form>Text Content
Menu Search * Home * News * Health Tech * Biopharma * Devices & Diagnostics * Consumer / Employer * Contributors * MedCity Influencers * MedCitizens * Events * Jobs * Research * Newsletters * About Us * Advertising * Contact us * Send Tips * Advertising * About * Twitter * Facebook * RSS * Subscribe via email X Close Signup Modal MEDCITY >> INBOX Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy. * Send Tips * Advertising * About * Twitter * Facebook * RSS * Subscribe via email MEDCITY NEWS LEVERAGING DATA ANALYTICS TO SUPPORT EMPLOYEE MENTAL WELL-BEING INVEST PHARMATECH: THE CONVERGENCE OF DIGITAL HEALTH AND BIOPHARMA PANDEMIC RESPONSE LAB CEO DISCUSSES ITS APPROACH TO LABORATORY AUTOMATION DEMYSTIFYING DIGITAL PATIENT FINANCIAL ENGAGEMENT: 4 WAYS AI CAN HELP NOVARTIS CANCER DRUG IS NOW FIRST APPROVED THERAPY FOR GROUP OF RARE, GENETIC DISEASES HAVE BACK, HIP OR KNEE PAIN? WHAT TO CONSIDER BEFORE SEEING AN ORTHOPEDIC SURGEON ISRAELI COMPANY’S ROBOT-ASSISTED DEVICE FOR PERCUTANEOUS RADIOLOGY PROCEDURES AIMS TO REDUCE READMISSIONS IMARA’S TWO TRIAL FLOPS IN BLOOD DISORDERS DIM DRUG’S PROSPECTS IN HEART FAILURE CORPORATE VENTURE CAPITAL-BACKED FUNDING FOR DIGITAL HEALTH STARTUPS INCREASED SHARPLY IN 2021 BUTLER UNIVERSITY DEBUTS MENTAL HEALTH APP FROM LIFEOMIC AND PREVENTIA TAKEDA RETURNS TO EVOZYNE’S AI TECH, SEEKING NOVEL PROTEINS FOR NEXT-GEN GENE THERAPIES BILINGUAL HEALTH CARE PLATFORM OFFERS 24/7 PRIMARY AND MULTI-SPECIALTY CARE TO SPANISH SPEAKERS HOW ADVANCED PLATFORMS FOR INFORMED CONSENT CAN REINFORCE TRUST IN CLINICAL TRIALS, IMPROVE COMPLIANCE HEALTHCARE HIRES OF NOTE FDA PLACES PARTIAL HOLD ON CURIS CANCER DRUG AFTER PATIENT DEATH IN CLINICAL TRIAL * News * Health Tech * BioPharma * Devices & Diagnostics * Consumer / Employer * Contributors * MedCity Influencers * MedCitizens * Events * INVEST * INVEST PharmaTech * INVEST Digital Health * INVEST Population Health * Jobs * Research * Newsletters Don’t miss MedCity INVEST 2022 – March 28-30 at the Ritz-Carlton Chicago Pharma, BioPharma NOVARTIS CANCER DRUG IS NOW FIRST APPROVED THERAPY FOR GROUP OF RARE, GENETIC DISEASES A NOVARTIS DRUG THAT STOPS ABNORMAL CELL GROWTH IN BREAST CANCER NOW HAS AN ADDITIONAL FDA APPROVAL TREATING A GROUP OF RARE DISORDERS CHARACTERIZED BY OVERGROWTH IN VARIOUS TYPES OF TISSUE. THE REGULATORY DECISION MAKES THE DRUG, VIJOICE, THE FIRST APPROVED THERAPY FOR THESE DISORDERS TERMED “PROS.” By Frank Vinluan Post a comment / Apr 6, 2022 at 1:46 PM 0Shares A genetic mutation is the root of “PROS,” a group of rare and debilitating disorders characterized by tissue overgrowth, mobility problems, and chronic pain. A Novartis drug that interferes with a pathway for the progression of these disorders is now approved by the FDA, making it the first therapy authorized by the agency for treating PROS patients. Promoted IMPORTANCE OF PATIENT CAPITAL IN LIFE SCIENCES TSX Venture Exchange has a strong history of helping early stage health and life sciences companies raise patient capital for research and development purposes. Daniel Lubienietzky, Toronto Stock Exchange The regulatory decision announced Wednesday covers patients age 2 and older who have severe cases of PROS that require systemic therapy. The drug, alpelisib, will be marketed for PROS under the name “Vijoice.” The acronym PROS stands for PIK3CA-Related Overgrowth Spectrum. PIK3CA is a gene that provides instructions for making phosphoinositide 3-kinases, which are enzymes that play key roles in cellular growth. Mutated versions of the protein cause cells to grow and divide abnormally. Alpelisib is a kinase inhibitor designed to block the mutated enzymes. Basel, Switzerland-based Novartis first tested alpelisib’s approach in cancer. In 2019, the FDA approved the drug for treating advanced cases of breast cancer characterized by a PIK3CA mutation. The drug’s efficacy was assessed in a pivotal study enrolling 572 patients. Alpelisib’s approval in breast cancer, which covered its use in combination the approved endocrine therapy fulvestrant, made the Novartis drug the first approved PI3K inhibitor. For the cancer indication, the pharmaceutical giant markets alpelisib under the name “Piqray.” The drug accounted for $329 million in sales last year, according to Novartis’s financial statements. Alpelisib’s approach to interfering with abnormal cell growth characteristic of breast cancer can also apply to the abnormal cell growth in other tissues in other parts of the body. PIK3CA mutations can lead to overgrowth in fat, muscle, nerve, and skeletal tissues. PROS disorders can also manifest as blood vessel malformations and skin lesions. Treatments for PROS include surgery or interventional radiology. Promoted SEPARATING HOPE FROM HYPE: THE NEED TO PRIORITIZE MENTAL HEALTH APPS WITH PROVEN RESULTS FOR CLINICAL CONDITIONS Imagine what replacing wellness solutions with digital therapeutics could do… Professor Colin Espie, PhD, Co-Founder and Chief Scientist at Big Health According to Novartis, the prevalence of PROS is about 14 cases per million people. The PROS classification stems from a National Institutes of Health workshop in 2013 where PROS researchers, support groups, and advocacy organizations proposed grouping the overgrowth conditions caused by PIK3CA mutations. The disorders falling under the PROS umbrella include KTS, CLOVES syndrome, FAVA, and CLAPO syndrome. For PROS, Novartis tested alpelisib in a single-arm study that used real-world data. The FDA said PROS patients age 2 and older were given the once-daily drug under an expanded access program for compassionate use. Alpelisib’s efficacy in PROS was evaluated in 37 patients who had at least one lesion identified by medical imaging 24 weeks before receiving the first dose of the drug. The main goal was to measure at week 24 the proportion of patients with a radiological response, defined as a 20% or greater reduction in lesion volume. The study also assessed the duration of the response to treatment. Of the 37 patients, 27% had a radiological response at week 24; of those responders, 60% had a response that lasted 12 months or longer. The most common adverse reactions reported in the study were diarrhea, an inflamed and sore mouth, and high blood sugar. The regulatory decision for Vijoice is an accelerated approval based on a thinner body of evidence than is typically required. Retaining approval status may require Novartis to provide additional clinical data to confirm the drug’s benefit. “Today’s approval of the first treatment for PROS offers hope for a better quality of life to patients and families affected by these rare conditions,” Kristen Davis, executive director of CLOVES Syndrome Community said in a prepared statement. “PROS conditions can be debilitating and disabling and can result in disruptions to everyday activities.” Photo by Novartis 0Shares This article is featured in the Healthcare Docket newsletter, a partnership between Breaking Media publications MedCity News and Above the Law. Enter your email address to subscribe. TOPICS Basel, cancer, Clinical Trials, FDA, Novartis, rare diseases, Switzerland HEAR THE LATEST INDUSTRY NEWS FIRST. SIGN UP FOR OUR DAILY NEWSLETTER. We will never sell or share your information without your consent. See our privacy policy. Promoted BETTER PRIMARY CARE ISN’T ONLY GOOD FOR HEALTH—IT’S GOOD FOR BUSINESS The rising cost of employer-sponsored healthcare makes it difficult for American businesses to compete globally. That doesn’t have to be the reality. Learn how one company changed its trajectory. Tom Gentile, CEO of Spirit AeroSystems & Richard Gephardt, Co-founder of SolidaritUS Health MEDCITY INVEST PHARMATECH JOIN US AT INVEST PHARMATECH 2022 MedCity INVEST PharmaTech, a virtual event to be held July 26, 2022 is a virtual executive summit where established biopharma companies gather with health tech and digital health innovators to transform the industry. Reserve your spot now.>> GOT NEWS? SEND US A TIP MEDCITY >> INBOX Get the latest industry news first when you subscribe to our newsletter. We will never sell or share your information without your consent. See our privacy policy. Promoted QUANTIFYING HEALTHCARE INTEROPERABILITY DURING COVID-19 A webinar, sponsored by Surescripts on April 28, will include: Surescripts CEO Tom Skelton, Epic CEO Judy Faulkner, Healthcare Leadership Council President Mary Grealy, and UC San Francisco Assistant Professor of Medicine A. Jay Holmgren. Register today! Surescripts and MedCity News × HEAR THE LATEST INDUSTRY NEWS FIRST. SIGN UP FOR OUR DAILY NEWSLETTER. No thanks We will never sell or share your information without your consent. See our privacy policy. Advertise About Newsletter Our Sites * * * * * * * © 2022 Breaking Media, Inc. All rights reserved. Registration or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Privacy Center | Do not sell my information 0Shares WELCOME TO MEDCITYNEWS MEDCITYNEWS ASKS FOR YOUR CONSENT TO USE YOUR PERSONAL DATA TO: * perm_identity Personalised ads and content, ad and content measurement, audience insights and product development * devices Store and/or access information on a device expand_moreremove Learn more * How can I change my choice? * What if I don't consent? * How does legitimate interest work? * Do I have to consent to everything? Your personal data will be processed and information from your device (cookies, unique identifiers, and other device data) may be stored by, accessed by and shared with third party vendors, or used specifically by this site or app. Some vendors may process your personal data on the basis of legitimate interest, which you can object to by managing your options below. Look for a link at the bottom of this page or in our privacy policy where you can withdraw consent. Consent Manage options arrow_back Data preferences MANAGE YOUR DATA You can choose how your personal data is used. Vendors want your permission to do the following: TCF vendors help_outline STORE AND/OR ACCESS INFORMATION ON A DEVICE Cookies, device identifiers, or other information can be stored or accessed on your device for the purposes presented to you. View details Consent SELECT BASIC ADS Ads can be shown to you based on the content you’re viewing, the app you’re using, your approximate location, or your device type. View details ConsentLegitimate interesthelp_outline CREATE A PERSONALISED ADS PROFILE A profile can be built about you and your interests to show you personalised ads that are relevant to you. View details ConsentLegitimate interesthelp_outline SELECT PERSONALISED ADS Personalised ads can be shown to you based on a profile about you. View details ConsentLegitimate interesthelp_outline CREATE A PERSONALISED CONTENT PROFILE A profile can be built about you and your interests to show you personalised content that is relevant to you. View details ConsentLegitimate interesthelp_outline SELECT PERSONALISED CONTENT Personalised content can be shown to you based on a profile about you. View details ConsentLegitimate interesthelp_outline MEASURE AD PERFORMANCE The performance and effectiveness of ads that you see or interact with can be measured. View details ConsentLegitimate interesthelp_outline MEASURE CONTENT PERFORMANCE The performance and effectiveness of content that you see or interact with can be measured. View details ConsentLegitimate interesthelp_outline APPLY MARKET RESEARCH TO GENERATE AUDIENCE INSIGHTS Market research can be used to learn more about the audiences who visit sites/apps and view ads. View details ConsentLegitimate interesthelp_outline DEVELOP AND IMPROVE PRODUCTS Your data can be used to improve existing systems and software, and to develop new products View details ConsentLegitimate interesthelp_outline ENSURE SECURITY, PREVENT FRAUD, AND DEBUG help_outline Your data can be used to monitor for and prevent fraudulent activity, and ensure systems and processes work properly and securely. View details TECHNICALLY DELIVER ADS OR CONTENT help_outline Your device can receive and send information that allows you to see and interact with ads and content. View details MATCH AND COMBINE OFFLINE DATA SOURCES help_outline Data from offline data sources can be combined with your online activity in support of one or more purposes View details LINK DIFFERENT DEVICES help_outline Different devices can be determined as belonging to you or your household in support of one or more of purposes. View details RECEIVE AND USE AUTOMATICALLY-SENT DEVICE CHARACTERISTICS FOR IDENTIFICATION help_outline Your device might be distinguished from other devices based on information it automatically sends, such as IP address or browser type. View details USE PRECISE GEOLOCATION DATA Your precise geolocation data can be used in support of one or more purposes. This means your location can be accurate to within several meters. View details Consent Vendor preferences Accept all Confirm choices arrow_back Vendor preferences CONFIRM OUR VENDORS Vendors can use your data to provide services. Declining a vendor can stop them from using the data you shared. TCF vendors help_outline EXPONENTIAL INTERACTIVE, INC D/B/A VDX.TV Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ROQ.AD INC. Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch Consent INDEX EXCHANGE, INC. Cookie duration: 395 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline QUANTCAST INTERNATIONAL LIMITED Cookie duration: 397 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BEESWAXIO CORPORATION Cookie duration: 395 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SOVRN HOLDINGS INC Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADIKTEEV Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline RTB HOUSE S.A. Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline WIDESPACE AB Cookie duration: 372 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch Consent THE TRADE DESK Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADMETRICS GMBH Doesn't use cookies. View details | Privacy policylaunch Consent AMOBEE INC. Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline EPSILON Cookie duration: 400 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline YAHOO EMEA LIMITED Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADVENTORI SAS Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TRIPLELIFT, INC. Cookie duration: 90 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline XANDR, INC. Cookie duration: 90 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEORY GMBH Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline UNRULY GROUP LLC Cookie duration: 395 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEURAL.ONE Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADITION TECHNOLOGIES GMBH Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ACTIVE AGENT (ADITION TECHNOLOGIES GMBH) Cookie duration: 90 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TABOOLA EUROPE LIMITED Cookie duration: 366 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMART ADSERVER Cookie duration: 396 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADFORM Cookie duration: 60 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MAGNITE, INC. Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADARA MEDIA UNLIMITED Cookie duration: 730 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SIFT MEDIA, INC Doesn't use cookies. View details | Privacy policylaunch Consent RAKUTEN MARKETING LLC Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline AVOCET SYSTEMS LIMITED Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LIFESTREET CORPORATION Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SIZMEK BY AMAZON Cookie duration: 396 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline OPENX Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline YIELDLAB AG Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ROKU ADVERTISING SERVICES Cookie duration: 731 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NANO INTERACTIVE GMBH Cookie duration: 182 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SIMPLIFI HOLDINGS INC Cookie duration: 366 (days). View details | Privacy policylaunch Consent PUBMATIC, INC. Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline COMSCORE B.V. Cookie duration: 720 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline FLASHTALKING, INC. Cookie duration: 730 (days). View details | Privacy policylaunch Consent MEDIAMATH, INC. Cookie duration: 393 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMAATO, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SEMASIO GMBH Cookie duration: 366 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch Consent CRIMTAN HOLDINGS LIMITED Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SCENE STEALER LIMITED Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BETGENIUS LTD Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TRESENSA TECHNOLOGIES, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CRITEO SA Cookie duration: 390 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADLOOX SA Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BLIS MEDIA LIMITED Cookie duration: 400 (days). Cookie duration resets each session. Uses other forms of storage. View details | Storage details | Privacy policylaunch ConsentLegitimate interesthelp_outline LOTAME SOLUTIONS, INC Cookie duration: 274 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LIVERAMP, INC. Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GROUPM UK LIMITED Cookie duration: 395 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LOOPME LIMITED Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline DYNATA LLC Cookie duration: 365 (days). View details | Privacy policylaunch Consent FUSIO BY S4M Cookie duration: 1 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TEEMO SA Cookie duration: 30 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline DOUBLEVERIFY INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BIDSWITCH GMBH Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline IPONWEB GMBH Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEXTROLL, INC. Cookie duration: 395 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TEADS Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline STRÖER SSP GMBH (SSP) Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline STRÖER SSP GMBH (DSP) Cookie duration: 90 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline PLATFORM161 B.V. Cookie duration: 396 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADACADO TECHNOLOGIES INC. (DBA ADACADO) Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MEETRICS GMBH Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMADEX, S.L.U. Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BOMBORA INC. Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SPOTX, INC Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline EASYMEDIA GMBH Cookie duration: 365 (days). Cookie duration resets each session. View details | Privacy policylaunch Consent REMERGE GMBH Doesn't use cookies. View details | Privacy policylaunch Consent ADVANCED STORE GMBH Cookie duration: 24856 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MAGNITE CTV, INC. Cookie duration: 366 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SPOTAD Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline DELTA PROJECTS AB Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline USEMAX ADVERTISEMENT (EMEGO GMBH) Cookie duration: 365 (days). Cookie duration resets each session. View details | Storage details | Privacy policylaunch ConsentLegitimate interesthelp_outline EMETRIQ GMBH Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline PUBLICIS MEDIA GMBH Cookie duration: 1827 (days). Uses other forms of storage. View details | Privacy policylaunch Consent MCCANN DISCIPLINE LTD Cookie duration: 14 (days). View details | Privacy policylaunch Consent ONETAG LIMITED Cookie duration: 741 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CLOUD TECHNOLOGIES S.A. Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SMARTOLOGY LIMITED Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline IMPROVE DIGITAL Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADOBE ADVERTISING CLOUD Cookie duration: 365 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline BANNERFLOW AB Cookie duration: 366 (days). View details | Storage details | Privacy policylaunch ConsentLegitimate interesthelp_outline TABMO SAS Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline INTEGRAL AD SCIENCE, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline WIZALY Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch Consent WEBORAMA Cookie duration: 393 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline JIVOX CORPORATION Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MOBILE PROFESSIONALS BV Cookie duration: Uses session cookies. View details | Privacy policylaunch Consent ON DEVICE RESEARCH LIMITED Cookie duration: 30 (days). View details | Privacy policylaunch Consent EXACTAG GMBH Cookie duration: 180 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CELTRA, INC. Doesn't use cookies. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MAINADV SRL Cookie duration: 1 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GEMIUS SA Cookie duration: 395 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch Consent THE KANTAR GROUP LIMITED Cookie duration: 914 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline IMPACT TECH INC. Cookie duration: 720 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NIELSEN MARKETING CLOUD Cookie duration: 120 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SOLOCAL Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline PIXALATE, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ORACLE DATA CLOUD Cookie duration: 180 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NUMBERLY Cookie duration: 396 (days). View details | Privacy policylaunch Consent AUDIENCEPROJECT APS Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline EFFILIATION / EFFINITY Cookie duration: 60 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ARRIVALIST CO Cookie duration: 730 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SEENTHIS AB Doesn't use cookies. View details | Privacy policylaunch COMMANDERS ACT Cookie duration: 365 (days). Uses other forms of storage. View details | Privacy policylaunch Consent TRAVEL AUDIENCE GMBH Cookie duration: 397 (days). View details | Storage details | Privacy policylaunch Consent HUMAN Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADLUDIO LTD. Doesn't use cookies. View details | Privacy policylaunch Consent NEODATA GROUP SRL Cookie duration: 366 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline INNOVID INC. Cookie duration: 92 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline TACTIC™ REAL-TIME MARKETING AS Cookie duration: Uses session cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline NEUSTAR, INC. Cookie duration: 3650 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SUBLIMESKINZ - ADLEDGE Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline SALESFORCE.COM, INC. Cookie duration: 180 (days). Uses other forms of storage. View details | Privacy policylaunch Consent VERVE GROUP EUROPE GMBH Doesn't use cookies. View details | Privacy policylaunch Consent KOCHAVA INC. Doesn't use cookies. View details | Privacy policylaunch Consent OTTO (GMBH & CO KG) Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ADOBE AUDIENCE MANAGER, ADOBE EXPERIENCE PLATFORM Cookie duration: 180 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LOCALSENSOR B.V. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline ONLINE SOLUTION Cookie duration: 365 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline RELAY42 NETHERLANDS B.V. Cookie duration: 731 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GP ONE GMBH Cookie duration: Uses session cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline LIFTOFF MOBILE, INC. Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MINDTAKE RESEARCH GMBH Cookie duration: 93 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline AAX LLC Cookie duration: 2191 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CINT AB Cookie duration: 730 (days). View details | Privacy policylaunch Consent GOOGLE ADVERTISING PRODUCTS Cookie duration: 396 (days). Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline GFK SE Cookie duration: 730 (days). Uses other forms of storage. View details | Privacy policylaunch Consent REVJET Cookie duration: 730 (days). View details | Privacy policylaunch Consent DIGISEG APS Doesn't use cookies. View details | Privacy policylaunch Consent PROTECTED MEDIA LTD Doesn't use cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline CLINCH LABS LTD Cookie duration: 730 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline HEARTS & SCIENCE MÜNCHEN GMBH Cookie duration: 60 (days). Cookie duration resets each session. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline AMAZON ADVERTISING Cookie duration: 396 (days). Cookie duration resets each session. Uses other forms of storage. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline MOLOCO, INC. Cookie duration: Uses session cookies. View details | Privacy policylaunch ConsentLegitimate interesthelp_outline OBJECTIVE PARTNERS BV Cookie duration: 90 (days). View details | Privacy policylaunch Consent EBAY INC Cookie duration: 90 (days). View details | Privacy policylaunch ConsentLegitimate interesthelp_outline General vendors help_outline GSKINNER Privacy policylaunch Consent AKAMAI Privacy policylaunch Consent FACEBOOK Privacy policylaunch Consent AUNICA Privacy policylaunch Consent BOOKING.COM Privacy policylaunch Consent C3 METRICS Privacy policylaunch Consent IBM Privacy policylaunch Consent ADTRIBA Privacy policylaunch Consent PULSEPOINT Privacy policylaunch Consent DEMANDBASE Privacy policylaunch Consent EVIDON Privacy policylaunch Consent CUBED Privacy policylaunch Consent HURRA.COM Privacy policylaunch Consent OPTOMATON Privacy policylaunch Consent INTELLIAD Privacy policylaunch Consent ANALIGHTS Privacy policylaunch Consent DSTILLERY Privacy policylaunch Consent DMA INSTITUTE Privacy policylaunch Consent ZMS Privacy policylaunch Consent DENTSU AEGIS NETWORK Privacy policylaunch Consent IGNITION ONE Privacy policylaunch Consent OMNICOM MEDIA GROUP Privacy policylaunch Consent RESONATE Privacy policylaunch Consent CENTRO Privacy policylaunch Consent SOJERN Privacy policylaunch Consent HAENSEL AMS Privacy policylaunch Consent BDSK HANDELS GMBH & CO. KG Privacy policylaunch Consent VIDEOLOGY Privacy policylaunch Consent TRADEDOUBLER AB Privacy policylaunch Consent TRUSTARC Privacy policylaunch Consent TRUEFFECT Privacy policylaunch Consent MARKETING SCIENCE CONSULTING GROUP, INC. Privacy policylaunch Consent DENTSU Privacy policylaunch Consent ESSENS Privacy policylaunch Consent TRAVEL DATA COLLECTIVE Privacy policylaunch Consent ADVOLUTION.CONTROL Privacy policylaunch Consent VIMEO Privacy policylaunch Consent ENSIGHTEN Privacy policylaunch Consent ADMAXIM Privacy policylaunch Consent BATCH MEDIA Privacy policylaunch Consent VODAFONE GMBH Privacy policylaunch Consent NETQUEST Privacy policylaunch Consent MANAGE.COM Privacy policylaunch Consent CLOUDFLARE Privacy policylaunch Consent SCOOTA Privacy policylaunch Consent HAVAS MEDIA FRANCE - DBI Privacy policylaunch Consent NETFLIX Privacy policylaunch Consent MACROMILL GROUP Privacy policylaunch Consent EBUILDERS Privacy policylaunch Consent APPLOVIN CORP. Privacy policylaunch Consent FRACTIONAL MEDIA Privacy policylaunch Consent RACKSPACE Privacy policylaunch Consent MSI-ACI Privacy policylaunch Consent NAVEGG Privacy policylaunch Consent ADMEDO Privacy policylaunch Consent MOBITRANS Privacy policylaunch Consent ADEX Privacy policylaunch Consent AARKI Privacy policylaunch Consent SFR Privacy policylaunch Consent CABLATO Privacy policylaunch Consent WAYSTACK Privacy policylaunch Consent Accept all Confirm choices Close Share this Article Friend's Email Address Your Name Your Email Address Comments Send Email Email sent! ×